Merck KEYTRUDA gets USFDA priority review for its Second Application Medical Dialogues Bureau9 April 2020 9:00 AM ISTKenilworth: Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted and...
Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer Medical Dialogues Bureau28 March 2020 11:45 AM ISTTEPMETKO is the first regulatory approval globally for an oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene...
Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough Medical Dialogues Bureau21 March 2020 10:15 AM ISTKenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...
Merck, AMCM collaborates for 3D Printing of Tablets Medical Dialogues Bureau1 March 2020 10:30 AM IST3D printing allows for API (active pharmaceutical development) formulation to be scalable while avoiding costly reformulations throughout the entire...
Merck Keytruda, Chemotherapy combo meets endpoint for first-line treatment of Breast Cancer Medical Dialogues Bureau18 Feb 2020 10:15 AM ISTNew Delhi: Merck known as MSD outside the United States and Canada, recently announced that the pivotal Phase 3 KEYNOTE-355 trial investigating...
Merck introduces BrightLab, cloud-based instrument connectivity platform for research scientists Medical Dialogues Bureau15 Feb 2020 10:15 AM ISTGermany: Merck, a leading science and technology company, recently introduced its BrightLab cloud-based inventory management and instrument...
Merck to spin-off biosimilar drugs business to focus on Keytruda Medical Dialogues Bureau7 Feb 2020 9:15 AM IST Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company...
Merck's antibacterial med Dificid Gets FDA nod in Pediatric Indication Medical Dialogues Bureau30 Jan 2020 3:50 PM ISTMerck & Co., Inc announced that the FDA has granted approval to its new drug application ("NDA") and a supplemental NDA (sNDA) for its...
Drugmajors slash prices by 53pc for China bulk-buy program eligibility Medical Dialogues Bureau20 Jan 2020 10:00 AM ISTBeijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest...
MSD India appoints Rehan A Khan as Managing Director Medical Dialogues Bureau10 Jan 2020 12:04 PM ISTRehan A Khan was also a board member and advisor to several impacts led Private Equity funds and to healthcare companies in Africa, India, and...
Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations Medical Dialogues Bureau24 Dec 2019 9:00 AM ISTThe vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that...
Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial Medical Dialogues Bureau3 Nov 2019 9:00 AM ISTBristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
